H.C. Wainwright Reiterates Xoma (XOMA) As Buy; Has PT Of $38.0; Shorts at Cantel Medical (CMD) Lowered By 8.35%

December 7, 2017 - By Henry Gaston

Among 7 analysts covering Xoma Limited (NASDAQ:XOMA), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Xoma Limited has $38 highest and $1.50 lowest target. $16.17’s average target is -49.67% below currents $32.13 stock price. Xoma Limited had 18 analyst reports since July 23, 2015 according to SRatingsIntel. Zacks downgraded the shares of XOMA in report on Friday, August 28 to “Buy” rating. The rating was reinitiated by H.C. Wainwright with “Buy” on Tuesday, October 17. As per Thursday, July 23, the company rating was downgraded by Jefferies. The firm has “Hold” rating given on Monday, August 14 by Wedbush. The firm has “Neutral” rating by Wedbush given on Monday, March 27. The firm earned “Neutral” rating on Wednesday, July 22 by Piper Jaffray. H.C. Wainwright maintained XOMA Corporation (NASDAQ:XOMA) on Tuesday, November 7 with “Buy” rating. On Thursday, August 10 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock of XOMA Corporation (NASDAQ:XOMA) has “Neutral” rating given on Wednesday, July 22 by Ladenburg Thalmann. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, November 14 report.

Cantel Medical Corporation (NYSE:CMD) had a decrease of 8.35% in short interest. CMD’s SI was 731,900 shares in December as released by FINRA. Its down 8.35% from 798,600 shares previously. With 118,400 avg volume, 6 days are for Cantel Medical Corporation (NYSE:CMD)’s short sellers to cover CMD’s short positions. The SI to Cantel Medical Corporation’s float is 2.07%. The stock increased 4.36% or $4.37 during the last trading session, reaching $104.58. About 85,462 shares traded. Cantel Medical Corp. (NYSE:CMD) has risen 11.32% since December 7, 2016 and is uptrending. It has underperformed by 5.38% the S&P500.

Among 2 analysts covering Cantel Medical (NYSE:CMD), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Cantel Medical had 2 analyst reports since March 17, 2017 according to SRatingsIntel. The rating was initiated by Raymond James on Friday, March 17 with “Mkt Perform”. As per Friday, June 9, the company rating was downgraded by Benchmark.

Cantel Medical Corp. provides infection prevention services and products for the healthcare market worldwide. The company has market cap of $4.39 billion. The firm operates through four divisions: Endoscopy, Water Purification and Filtration, Healthcare Disposables, and Dialysis. It has a 61.16 P/E ratio. The Endoscopy segment offers automated endoscope reprocessing systems; detergents; leak testing and manual cleaning products; storage cabinets; transport systems; mobile medical carts; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid and flexible endoscopes, and other instrumentation; cleaning and disinfecting reusable components used in gastrointestinal endoscopy procedures; and technical maintenance services.

The stock increased 9.47% or $2.78 during the last trading session, reaching $32.13. About 129,644 shares traded. XOMA Corporation (NASDAQ:XOMA) has declined 51.66% since December 7, 2016 and is downtrending. It has underperformed by 68.36% the S&P500.

Analysts await XOMA Corporation (NASDAQ:XOMA) to report earnings on March, 15. They expect $-0.50 earnings per share, up 82.70% or $2.39 from last year’s $-2.89 per share. After $1.98 actual earnings per share reported by XOMA Corporation for the previous quarter, Wall Street now forecasts -125.25% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: